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Levamisole (LMS), the levoisomer of 2,3,5,6-tetrahydro-6-phenylimidazo [2, l-b] thia- 
zole hydrochloride, has demonstrated immunoenhancing  activities on mouse responsive- 
ness  to  antigenic stimuli  (1-4).  This  activity depended  upon  T-cell  potentiation as 
evidenced by increased gra~-versus-host reaction when donors were treated by LMS (5), 
by accelerated rejection of isogeneic skin grafts (6,  7), or by enhanced levels of delayed 
hypersensitivity in LMS-treated mice (7). Sodium diethyldithiocarbamate, DTC, a non- 
cyclic sulphur drug, induced similar responses (8).  LMS effect can be transferred by a 
serum factor obtained from animals after treatment with LMS. In transfer experiments, 
this factor enforced immune responses to sheep red cells (SRC)  in recipient mice and 
induced regression of tumor size in leukemic AKR mice, even when leukemic mice have 
failed to  respond to  treatment with  LMS  (9,  10). On the  other  hand,  the  impaired 
development of T  ceils  in nu/nu  mice  has  been  ascribed to  lack  of the  maturation 
stimulus, or stimuli, normally provided by thymus factors (11-15). 
In this report, we present evidences that LMS or DTC induce in vivo acquisi- 
tion of specific T-cell markers by undifferentiated precursor lymphoid cells of 
thymusless nude mice and concomitantly induce functional immune activation. 
Also, that serum from treated nu/nu mice can transfer these in vivo activities 
and allow in vitro differentiation of precursor cells into T cells. 
Materials and Methods 
Healthy nu/nu mice from the Edinburgh strain (16), obtained from the Centre de Sdlection des 
Animaux de Laboratoire (CNRS, Orldans, France), were maintained in an air-conditioned room 
and partially protected  from  environmental infections by Isocap filters (Iffa-Credo,  l'Arbresle, 
France). 
LMS or DTC were dissolved in pyrogen-free saline and subcutaneously administered in vol of 
0.2 mt, at the doses indicated in the individual  experiments. Doses of the drug were expressed  in 
milligrams of the salt per kilogram body weight. 
In in vivo assays,  5- to 6-wk-old female nu/nu  mice  were killed 4 days after a  single drug 
administration. Any mouse  showing evidence of liver disease  (17) was  discarded  from  the 
experiment. In vitro induction assays were performed for  2.5  h  at 37°C in a  humidified CO2 
incubator in the absence or presence of LMS or DTC. Amounts of the drugs varied from 10  -s to 10  -~ 
mM/10  ~  lymphocytes per ml of medium. Expression ofT-cell antigens on the cell surface was tested 
on either in vitro or in vivo induced lymphocyte suspensions in the cytotoxicity  assay (18), using 
Thy-l.2 and TL 1,  2,  3 antisera kindly provided  by E.  A.  Boyse. Each cytotoxicity assay was 
performed in duplicate. Induction of an acquired functional (helper) activity was assayed on day 4 
after immunization  of nu/nu mice with SRC and simultaneous treatment with LMS or with DTC 
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and expressed as IgM-(direct) or IgG-(indirect) plaque-forming spleen cells (PFC),  using a  tech- 
nique previously described (1, 2, 9). Transfer of inducing activity was tested by induction assay of 
spleen cells or bone marrow cells ofnu/nu mice in the presence of serum from nu/nu mice treated 
with 25 mg/kg LMS.  Transfer of functional immunocompetence was assayed by the PFC test in 
C3H/He female mice immunized with SRC and treated with serum of LMS-treated nu/nu  mice. 
The Limulus assay (19) (Pyrotest, Difco Laboratories, Detroit, Mich.) was used to detect contami- 
nant endotoxin before in vitro addition or to in vivo injection, and any assay performed with a 
sample that resulted even questionable for trace amount of endotoxin was discarded from the 
experiment. Flotation of cell suspensions in bovine serum albumin (BSA) to obtain prothymocyte- 
enriched populations was not used since available batches of BSA were contaminated with endo- 
toxin-like products in the Limulus assay. 
Results 
Our studies show that healthy nu/nu mice had few or no cells bearing T-cell 
markers  in the absence of activation by an overt or remote administration  of 
endotoxin (20) or by mouse hepatitis virus infection (17). Under these conditions, 
T cells could be induced in vivo in healthy nu/nu mice by an injection of LMS or 
DTC (Table I). In vivo induction of spleen prothymocyte differentiation by LMS 
or by DTC gave rise to cells of the TL- Thy 1  ÷ phenotype. This is the phenotype 
of peripheral  T  cells  and  of the  medullary thymocyte.  This  fast induction  of 
functional T cells takes place only in the spleen, suggesting prothymocytes are 
absent in lymph nodes  (Table I).  The acquisition of a  cytotypic T-cell surface 
marker after a single treatment with LMS or DTC compared favorably with the 
effects of repeatedly administering  preparations  from thymus  (17,  20).  In con- 
trast to the effects of thymopoietin (17, 21), precursor cells from spleen ofnu/nu 
thymusless mice incubated with LMS or DTC did not differentiate into T cells 
(data not tabulated,  as similar to controls). 
Administration of LMS or DTC evoked in SRC-immunized nu/nu mice signifi- 
cant numbers of IgG-PFC which were not present in immunized but untreated 
control animals  (Table II). An early switch from IgM to IgG antibody synthesis 
is  a  known  effect  of activated  T  lymphocytes  (22).  Therefore,  present  data 
confirm that LMS and DTC are in vivo able both to recruit and to activate the T- 
cell lineage (5-10). Inducing or immunostimulating  in vivo activities of LMS or 
of DTC  are likely associated with their  sulphur  moiety  (8,  23),  since DTC  is 
devoid of the imidazole ring. 
Nu/nu mice treated with LMS produced a factor that was absent from serum 
of untreated  mice.  This  factor  allowed both  in  vitro  induction  of thymocyte 
differentiation  and  transfer  of immune  stimulation.  Indeed,  when  precursor 
cells from spleen or bone marrow ofnu/nu mice were incubated in the presence 
of serum from LMS-treated nude mice, they express thymocyte markers (Table 
III).  The  inducing  activity  of serum  from  LMS-treated  nu/nu  mice  could be 
compared to the in vitro efficiency of thymus extracts (17, 18, 20, 21) or of thymic 
serum  factors  (14,  15). Functional  activation  was evidenced by a  twofold en- 
hancement of the immune response to SRC evoked by administering to C3H/He 
mice as little as 0.2 ml of serum from nu/nu mice treated with LMS (Table IV). 
Discussion 
Sulphur derivatives, LMS or DTC, administered to nu/nu mice, can induce in 
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TABLE I 
Proportions of Thy-I +  and TL + Cells in Spleen or Lymph Nodes of nu/nu Mice 4 Days 
after a Single Administration of LMS or DTC 
Percent of  T-antlgen-bearing  cells  in: 
Treatment  Spleen 
Thy-I  +  TL  ÷ 
Lymph nodes Thy-l  + or TL  + 
Saline  3, 4, 6, 6,  "<5, <5, 6, 7  <5, <5, <5 
LMS 2.5  7, 10, 10, 11, 14  O, 5, 5, 6, 9,  <5, <5, <5 
25  19, 28, 38, 43  9, 9, 12, 16 
DTC 2.5  15,  17, 17, 25, 29  3, 5, 7, 7, 8  <5, <5, <5 
25  17, 16, 21, 22, 23  4, 5, 5, 7, 9  <5, <5 
Cell suspensions, made separately from spleen and from pooled axillary,  messnterie, and inguinal lymph nodes, were adjusted at 5 
× 106 nucleated viable (trypan blue assay) cells  in RPMI 1640 medium (Grand Island Biological Company,  Grand Island, N. Y.) 
supplemented with 1% IgG-free calf  serum. The percentage of  in vivo induced cells  was calculated according to the formula 100 × 
(a-b)/a, where a = percent live  cells  after  incubation with rabbit complement and b = percent live  cells  after incubation with 
antiserum and complement. All data are values for individual mice. 
TABLE II 
In Vivo Helper Effects of Treatment with LMS or DTC on nu/nu 
Mice Responsiveness to Intravenous Immunization with 106 SRC 
Treatment (mg/kg drug) 
PFC/10  a  spleen cells 
IgM  IgG 
None  0,  0,  O  O,  0,  0 
LMS  alone, 25  O,  0,  0  0,  0,  O 
SRC alone  61,  75, 75  0,  0,  0 
SRC + LMS, 2.5  74, 101  88, 116 
SRC  +  LMS, 25  60,  72, 75  245, 190, 215 
SRC  +  DTC, 25  95, 107  35,  63 
Acquired functional activity  was assayed on day 4 postimmunization  and simultaneous  s.c. 
treatment. All data are values for  individual mice. Negative Limulus assays indicated less  than 
0.5 ng endotoxin per ml of injected  suspensions. Note that, healthy nulnu mice, not contami- 
nated by endotoxin or disease, did not demonstrate "background" PFC. 
TAELE HI 
In Vitro Generation of T  Cells from Spleen or Bone Marrow 
Precursor Cells by the Action of Serum of LMS-Treated nu/nu 
Mice 
Percent of  T-antigen-bearing  cells 
Treatment  Spleen  Bone marrow 
Thy-l*  TL  ÷  Thy-1  ÷  TL* 
None  <5,  <5  <5,  <5  <5,6 
NMS (1%)  0, 2  O, 0  2 
LMS-tS 
(1:5)  18, I0  6, 8 
(1:10)  I0, 12  9, 6 
<5,  <5 
0 
17, 18 
NT 
Induction  assays  were performed  on  5  ×  106 cells suspended  in  1  ml of 1640 medium  and 
incubated for 2.5 h at 37°C in a humidified CO~ incubator in the presence or absence of serum to 
be tested which was replaced in controls ("None" treatment) by 1% of IgG-free fetal calf serum. 
Normal mouse serum (NMS) was sampled on normal healthy 6-wk-old female nu/nu mice. LMS- 
tS was a pool  of sera from female nu/nu  mice collected 24 h  after a  treatment with 25 rng/kg 
LMS.  Negative Limulus  assays  indicated less than 0.5 ng endotoxin  per ml  of nude  mouse 
serum. Figures between brackets indicate  final  concentrations of  NMS  or  of  LMS-tS in  induction 
assays. Proportions of Thy-1  + or af TL  + cells  were calculated from the cytotoxicity  test  as in 
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TABLE IV 
Serum Transfer of  Immune Stimulation from LMS-Treated nu/ 
nu Mice to Untreated Recipient C3H/He Mice 
Treatment 
PFC/10  ~ spleen cells 
IRM  IgG 
None  10 _+  5  0 
SRC  264 ±  41  19 ±  2 
SRC  +  NMS  196 ±  37  13 _+ 3 
SRC  +  LMS-tS 
0.5 ml  466  ±  53  36 --_ 4 
0,2 ml  531 ±  65  49 ±  4 
Pooled serum (LMS-tS), collected from healthy nu/nu mice 24 h after a treatment with 25 mg/kg 
LMS, was administered i.p. to 6- to 8-wk-old female C3H/He mice, at doses of either 0.2 or 0.5 
ml, simultaneously to an i.e. immunization with 10  e SRC.  Normal mouse serum  (NMS) was 
sampled from untreated  healthy nu/nu  mice. Limulus  assays were negative, indicating less 
than 0.5 ng endotoxin  in  1 ml of these  sera.  [gM- and IgG-antibody PFC were evaluated as 
described for Table II. Means of 4  ±  SE. 
sufficient to restore a T-cell-mediated immune function. However, LMS or DTC 
are  unable  to replace  thymopoietin  (17,  20),  ubiquitin  (24),  Trainin's  thymic 
humoral  factor  (25),  Bach's  circulating  thymic  factor  (26),  poly A:U  (20),  or 
endotoxin (20) for in vitro inducing activity. 
LMS or DTC exert their activity through an indirect pathway. They induce a 
nonthymic cellular system to produce a factor released in the serum. This factor, 
in turn, induced T-cell differentiation and activation. In current studies, hepato- 
cytes or macrophages are candidates for the release of such a  factor. 
Our results are compatible with a  function of epithelial thymus which could 
be, in essence, the release of a hormone allowing a still unidentified cell system 
to synthesize and excrete a factor that supplies the signal for T-cell differentia- 
tion.  Thymectomy or genetic deficiency of thymus development will suppress 
the production of the thymic hormone, therefore suppressing excretion of the so- 
called  "thymic-factors."  In  vivo treatment  with  sulphur  derivatives,  LMS or 
DTC, can substitute in immune events for an alleged thymic hormone. 
Summary 
Levamisole and sodium diethyldithiocarbamate can induce in vivo thymocyte 
differentiation  from  precursor  spleen  cells of nu/nu  mice  and  evoke indirect 
plaque-forming  cells  in  nude  mice  immunized  with  sheep  red  cells.  These 
sulphur drugs induce in thymusless mice the production of a serum factor which 
transfer in vivo immune enhancement and in vitro thymocyte differentiation. In 
vivo  treatment  with sulphur  derivative can substitute for an alleged thymice 
hormone. 
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